Eton Pharmaceuticals and Aquestive Sign U.S. Licensing Deal for LIBERVANT® Buccal Film

Eton Pharmaceuticals and Aquestive Therapeutics have struck an exclusive agreement for LIBERVANT®, a buccal film treatment for seizure clusters. This partnership taps into a growing market, potentially exceeding $450 million annually in the U.S.